Pharmaceutical Industry Information Portal

HomeNewsletter

Newsletter

Veru’s new drug COVID-19 reduces deaths by 55% among hospitalized patients in an interim analysis of a phase 3 study

Veru Inc., an oncology biopharmaceutical company, April 11th announced positive efficacy and safety results of Phase 3 COVID-19 clinical trial evaluating oral sabizabulin versus...

Glenmark received approval to conduct clinical trials of its small molecule on patients with solid tumors and Hodgkin’s lymphoma

Glenmark Pharmaceuticals Limited, an innovation-driven, the global pharmaceutical company announced that its subsidiary Glenmark Specialty S.A. (Glenmark) received approval from the Indian drug regulator,...

PRAC finds no causal link between Comirnaty and Spikevax mRNA COVID-19 vaccines and autoimmune hepatitis

The April 4-7, 2022 Pharmacovigilance Risk Assessment Committee (PRAC) meeting noted no link between COVID vaccines and autoimmune hepatitis (AIH). The PRAC has concluded that...

CureVac and GSK contract with German government enabling rapid availability of 80 million mRNA-based vaccine

CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), and GSK today announced that...

Moderna, IAVI – new collaboration on the use of mRNA technology

Moderna, Inc. and the nonprofit scientific research organization IAVI, on April 7th, announced a new collaboration to employ mRNA technology to meet the challenge...

Jazz’s first immuno-oncology program in the company’s portfolio

Jazz Pharmaceuticals plc and Werewolf Therapeutics, Inc. On Thursday announced that the companies have entered into a licensing agreement under which Jazz has acquired...
spot_img

Expert Articles

spot_img